
|Videos|July 23, 2013
Episode 4 - A Clinical Overview of Hemophilia
Advertisement
Hemophilia is a congenital deficiency of vital clotting factors that are needed to form blood clots at the site of vascular injury. As an X-linked recessive disease, only males are clinically impacted by hemophilia, whereas females are only carriers for the bleeding disorder. Often presenting in early childhood, patients who are not optimally treated may experience bleeding episodes, reduced physical activity, decreased social participation, and long-term hemophilic arthropathy. As a consequence, hemophilia is a serious condition that is tied to substantial clinical and economic burdens, a negative impact on patient quality of life, and must be managed appropriately.
Advertisement
Related to this article

Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.

Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.

ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.

Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.

Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.

Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
4
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
5



















